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THE EFFECTS OF GENE KNOCKOUTS AND OVER-EXPRESSIONS ON CCN 
FAMILY PROTEINS IN ANGIOGENESIS  
 
SPIRO NECTARIOS HALIOTIS 
ABSTRACT 
 Blood Vessel growth is an intricate process normally characterized through the 
processes of vasculogenesis and angiogenesis. Vasculogenesis is the process of blood 
vessel formation via differentiation of early progenitor cells into endothelial cells. 
Angiogenesis is physiological process by which new blood vessels form and develop 
from pre-existing vessels, these vessels are critical for allowing the delivery of oxygen 
and nutrients to the body’s organs and tissues, which allows for proper growth and 
development. However, blood vessel growth has been shown to develop pathologically as 
well as physiologically. Pathological instances have been observed in a plethora of 
microvasculature diseases, especially in the eye. These microvasculature diseases 
include: Diabetic Retinopathy (DR) and vitreoretinopathy, retinopathy of prematurity 
(ROP), wet age-related macular degeneration (AMD), and neovascular glaucoma. 
Furthermore, unrestrained blood vessel growth via angiogenesis has been noted in being 
playing a critical role in tumor cell growth, proliferation, and metastasis. In an attempt 
understand the development of these pathologies, research has been conducted to further 
characterize the specific roles of genes which play a role in the mechanistic pathway of 
blood vessel growth and formation. Extracellular Matrix (ECM) proteins, which are 
critical in all aspects of vascular development and health, have been shown to play a role 
in modulation of angiogenetic growth and transcription factors. One particular 
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matricellular protein family, cellular communication network, has been shown to play a 
critical role in the modulation and control of ECM composition and morphology. It is 
also said that CCN proteins influence physiological and pathological Angiogenic and 
Neovascularization processes. Further knowledge and understanding of the mechanistic 
pathways of CCN proteins on Angiogenesis and Neovascularization could allow for 
possible drug therapy aimed at mitigation of unrestrained blood vessel growth in 
pathologies of the eye. Such research could also be utilized for targeted drug therapies on 
tumors, as past studies have shown cancer development depends on blood supply to 
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Blood vessels supply nutrients, oxygen, metabolites, chemical mediators, and even 
metabolic waste from cell to cell in order to properly maintain a balanced homeostasis of 
the immune system, body temperature, and pH (Teleanu et al., 2019). Blood vessels also 
allow for proper embryonic growth, development, and wound healing. Critical processes 
that promote proper blood vessel growth can be seen in early embryonic endothelial 
progenitors, which are recruited and differentiate into mature vascular endothelial cells 
with proper stimulation via local environmental factors (Herbert & Stainier, 2011). While 
this process is critical for development and function, instances of pathological 
neovascularization have been shown to occur as a result of disease driven states in the 
body. One area of the body where such pathologies are known to occur is in the eyes, 
particularly the retina. DR, AMD, and ROP are some of the few neovascular and 
fibrovascular diseases associated with a disruption in proper oxygen and nutrient due to 
improper vascular growth and development (Chaqour & Karrasch, 2020).  
 
Neovascularization and angiogenesis have also been observed in tumor growth beyond 1-
2 mm in diameter (Weidner et al., 1991; Cao, 2009). Tumor tissues possess a high 
propensity for angiogenesis. Combinations of ECM remodeling, upregulation of 
angiogenic factors, and endothelial proliferation contributes to the formation of tumor 
vessels (Jiang et al., 2020). Tumor neovascularization supplies oxygen and nutrients as 
well as removes metabolic waste. This neovascularization also can also change the 
microenvironment of the tumor to promote possible metastasis from primary location. In 
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comparison to normal vasculature, tumor vessels are immature and lack mural adhesion 
cells which can lead to vascular hyperpermeability, poor perfusion, and hypoxia (Jiang et 
al., 2020).  
 
One possible field of interest that has been shown to be critical in vascular development 
and health is the ECM. The ECM has been showed to support cell anchorage, structure, 
organization and mechanical stability, all of which are influenced via growth factors 
(Chaqour & Karrasch, 2020). It has been shown that possible changes to the composition 
in ECM protein expression can lead to abnormalities in vascular expression, which 
further exacerbates the possibility of pathological diseases. Research has hinted that 
vascular cells operate off of physical forces, such as ECM stiffness, which leads to 
upregulation of downstream matricellular proteins (Chaqour & Karrasch, 2020). Two 
such matricellular proteins are cellular communication network 1 and 2 (CCN1 & 
CCN2/CTGF), both of which have been shown to play a role in neovascularization and 
angiogenesis. Over-expressions and knockouts of other genes have also been showed to 
dramatically influence the two CCN family proteins, and in turn blood vessel growth. 
Overall, a better understanding of the mechanistic pathways and proteins of the ECM 
could provide answers to the pathological origins of retinal blinding diseases as well as 
tumor growth.  
 
This thesis will revolve around the process of angiogenesis as well as the CCN proteins 
which are said to play a critical role in controlling the process both pathologically and 
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physiologically. A brief explanation on the physiological process of angiogenesis and 
neovascularization will be given, followed by an overview of the retina, where a majority 
of the pathologies that will be discussed occur. In addition to the blind diseases in the 
eye, tumor growth caused by angiogenesis is a critical aspect for research in the field and 
will be mentioned. The ECM, which has been said to influence angiogenesis and 
neovascularization through upregulation and downregulation of specific genes will be 
reviewed and also be referenced in overexpression and knockout studies.  
 
Angiogenesis: Role and Development 
The vasculature is one of the first proper functioning organs to form during the process of 
embryogenesis. During the maturation process, differentiation and proliferation, as a 
result of signal regulation, creates the closed cardiovascular system which allows for the 
proper direction and control of blood flow. This intricate network comprises of large and 
medium sized vessels to even micrometer diameter capillaries. Overall, the vasculature in 
a human adult’s body adds up to nearly 90,000 km (Eelen et al, 2018). The role of the 
vasculature is to supply tissues and organs with nutrients and oxygen in order to maintain 
proper homeostasis and function.  
 
The first step in embryonic development of blood vessels is through the creation of a 
primitive vascular plexus through the process of vasculogenesis (Figure 1). The process 
begins with mesodermal angioblasts (Endothelial Cell Progenitors) aggregating together. 
Hemangioblasts, a precursor cell shared by both Endothelial Cells (EC) and 
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hematopoietic cells, has also been thought of as being a possible source for the formation 
of endothelium. (Eelen et al., 2018). Creation of the primitive vascular plexus is followed 
by growth and remodeling stages, where vessel formation (intussusception) and vessel 
sprouting (angiogenesis) take place.  
Intussusception enlarges and expands the capillary bed via “splitting” a singular capillary 
into two adjacent vessels. Meanwhile, EC’s begin to contact each other via local signals 
to go into the capillary lumen and begin formation of an endothelial bilayer linking 
together via intracellular junctions. Lastly, myofibroblasts and pericytes begin to bind 
onto the newly formed capillary, increasing the size of the vessel and allowing for 
splitting to occur.  
 
Figure 1. Formation of Primitive Vascular Plexus and Angiogenesis. Early progenitor 
cells located in the mesoderm differentiate into angioblasts (EC progenitors), eventually 
forming into tube-like shapes (primitive vascular plexus). These tube-like vessels than 
remodel extensively through intussusception and angiogenesis, leading to the creation of 




The next step following intussusception is vessel sprouting, or angiogenesis. 
Angiogenesis is driven by a series of mechanistic processes known as pro-angiogenic 
stimuli. This drive is normally caused by the surrounding tissues need for oxygen and 
nutrients, which leads to the secretion of Vascular Endothelial Growth factor (VEGF), 
Fibroblast Growth Factor (FGF), and many other pro-angiogenic stimuli (Carmeliet & 
Jain, 2011). Once VEGF arrives at the existing vessel, it binds onto its receptor, VEGF 
receptor 2 (VEGFR2) on EC’s. This is followed by what is known as “relaxation” of the 
pre-existing vessel. Endothelial cell-cell contacts breakdown, pericytes detach, and the 
basement membrane begins to break down. This process has been extensively studied in 
retinal angiogenesis, and is takes place in a highly coordinated in manner. It is stated that 
the EC which is exposed to the highest VEGF levels is chosen to become the “tip cell”, 
which leads all subsequent cells in migratory fashion towards the source of the originally 
released growth factor (Wacker & Gerhardt, 2011). During the process of migration, the 
“sprouting” vessels elongate via proliferation in the number of cells preceding the lead tip 
cell. These cells are known as “stalk” cells.  
  
Stalk and Tip cells, although from the same preexisting vessel, possess differences in 
both function and morphology. Tip cells comprise of numerous filopodia and protrusions, 
making them fairly motile. On the other hand, stalk cells have fewer filopodia (Gerhardt 
et al., 2003). Furthermore, Tip specification is highly dynamic in that only the fittest EC’s 
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are selected for the tip position to lead the sprouting of a new vessel. The process itself is 
called “tip cell overtaking” (Jakobsson et al., 2010).  
 
Once a tip cell is selected, neighboring EC’s are maintained as stalk cells via expression 
of Notch ligand Delta-like 4 (Dll4). This ligand is released via the tip cell and binds onto 
Notch receptors on adjacent EC’s. This then causes the Notch intracellular domain 
(NICD) to be released and eventually upregulate the expression of a high affinity/low 
activity “decoy” VEGF receptor 1 (VEGFR1) (Figure 2). At the same time, NICD 
inhibits the expression of the normally functioning VEGFR2. (Funahashi et al., 2010).  
Overall, the increase in the VEGF1:VEGFR2 ratio decreases the responsiveness of 
nearby EC’s to the VEGF ligands being released and establishes a stalk cell phenotype 
instead (Phng & Gerhardt, 2009). Through this continued process known as “cell 
shuffling”, the EC with the lowest VEGFR1/VEGFR2 ratio is deemed to be the fittest, 
and will obtain the position of tip cell (Arima & Nishiyama, 2011). Figure 2 below 











Figure 2. Tip Cells versus Stalk Cell Specification. During sprouting angiogenesis in 
the development of a new vessel, the VEGF gradient from pro-angiogenic cues binds to 
the VEGFR2 receptor leading to the upregulation of VEGFR2 for expression on the tip 
cell membrane as well as Dll4 ligand expression. Dll4 ligands will than bind to Notch 
receptors on neighboring EC’s, causing release of NICD from the membrane. NICD 
proceeds to upregulate the expression of “decoy” VEGFR1 as well as downregulate 
VEGFR2. It is this VEGFR1/VEGFR2 ratio which determines whether EC’s will adopt a 
stalk or tip cell phenotype. Figure taken from (Eelen et al., 2018)  
 
The process of shuffling not only assists in tip cell selection, but also causes constant 
changes in cell-cell interactions, specifically the Dll4-Notch lateral-inhibition 
mechanism. Such interactions could explain the fact that in the new sprout, Dll4 levels 
will fluctuate in each individual EC. This ensures that each EC possesses different 
behavior with respect to the mechanism previously described. Additional studies have 
also shown that the process of tip cell overtaking does not change substantially with 
either increase in VEGF or Dll4-Notch signaling inhibition (Arima et al., 2011). This 
showcases that tip cell overtake is merely a side effect of the sprouting formation, and 
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that the VEGF-Dll4-Notch pathway allows for a natural random selection of the tip cell 
rather than dictation of which EC takes on the position (Boas & Merks, 2015).  
 
“Phalanx cells” are another cell type observed to connect with the growing sprout with 
preexisting vessels (Mazzone et al., 2009). This allows for the formation of a lumen and 
eventual blood flow to occur. In order to form a closed system to allow for blood flow, 
sprouts will meet and have their tip cells fuse together. This process is known as 
anastomosis (Figure 3). Macrophages, through the secretion of pro-angiogenic factors, 
play the role of combining the two anastomosing tip cells (Fantin et al., 2010). Once 
anastomosis is complete, cells will organize to create a lumen to allow proper blood flow. 
Although not fully understood, recent studies have shown that hemodynamic force of 
blood flow could lead to lumen formation. This has been termed “inverse bleeding”, and 
includes blood pressure driving the stimulation of the apical membrane of EC’s. The 
EC’s then begin to contract their actomyosin, leading to lumen expansion (Gebala et al., 
2016). This usually takes place with the recruitment of platelet-derived growth factor 
(PDGF) receptor β (PDGFβ) expression cells via secretion of PDGF-β by EC’s. (Gaengel 




Figure 3. Anastomosis. Tip cell fusion from newly formed sprouts is caused by the 
secretion of proangiogenic factors via neighboring macrophages. Possible hemodynamic 
force of blood flow has been stated to follow this top cell fusion, furthering lumen 
expansion via “inverse bleeding”. Figure taken from (Eelen et al., 2018)  
 
 
Tumor Growth Factors and Angiogenesis 
 
In what was previously described as mutant cells undergoing clonal expansion, the tumor 
is quickly being seen more in light as an organ more so than a simple singular change in 
genomic expression. Although genetic deletions, overexpressions, mutations, and 
translocations play a role in the transformation of normal cells into malignant ones, 
research has shown that proper tumor growth and expansion is dependent on favorable 
ecosystems (Rak et al., 1995). This tumor micro-environment causes an alteration in gene 
expression in cells, leading to a change in normal tissue homeostasis. Such alterations 
normally feature secretion of molecules such as cytokines and growth factors. Tumors 
also are usually are comprised of a variety of cells, such as cancer-associated fibroblasts 
(CAFs), EC’s, pericytes, adipocytes, and even immune cells (Zuazo-Gaztelu & 
Casanovas, 2018). These cells, located in ECM, are constantly affected by changes in 
 
10 
environmental oxygenation and pH levels (Hanahan & Weinberg, 2011) (Figure 4). As a 
result, recent findings have shifted research into better understanding stromal elements 
which are believed to play a key role in tumor initiation, proliferation, and metastization. 
However, tumor cells have also been shown to copy many general physiological 
processes as a result of their unique microenvironment. The process of Angiogenesis has 
been acknowledged as being critical for tumor growth and survival (Mittal & Ebos, 
2014).  
 
Figure 4. Tumor Ecosystem. A basic microenvironment associated with tumor growth 
is comprised of a multitude of cells and growth factors. There will normally be a mix of 
both tumor and normal cells, as well as associated cells in the box shown. Figure taken 









Like all other cells, tumor cells are no different in that they need oxygen, nutrients, and 
waste disposal to grow. For this reason, blood vessel growth through early activated 
angiogenic processes are necessary to ensure growth and expansion in the tumor 
microenvironment. Blood vessel growth also plays a role in facilitating the dispersion of 
tumor cells to other location in the body. Thus, it can be stated that blood vessel growth 
promotes metastasis (Zuazo-Gaztelu & Casanovas, 2018). Instances of hypoxia and lack 
of nutrients are said to kickstart the expression of proangiogenic factors in tumor cells. 
This promotes the expression of inflammatory signals and cytokines that recruit vascular 
cells for vessel plexus formation (Muz  et al., 2015). Hypoxia also causes upregulation of 
key intermediaries in angiogenesis, such as VEGF and PDGF (Yang et al., 2013).  
 
Neovascularization is comprised of vasculogenesis and sprouting angiogenesis (Figure 
5).  Tumor progression and creation uses neovascularization in order to supply cells with 
necessary oxygen, nutrients, and proper waste removal. This is normally done by 
changing balance between proangiogenic factors and endothelial proliferation 
suppressors (Geudens & Gerhardt, 2011). In a tumor microenvironment, this balance 
shifts in favor of proangiogenic factors. As a result, there is a generation of sprouting 
angiogenic processes which if not properly controlled produce abnormal vascular 
structures.  
 
Normally, vasculogenesis involves the formation of the vascular plexus from the 
mesoderm through differentiation of angioblasts (Risau, 1997) (Figure 5). Meanwhile, 
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tumor vasculogenesis causes endothelial progenitor cells (EPC’s) to be recruited via 
chemokines, cytokines, and growth factors from tumor and stromal cells (Figure 5). This 
recruitment begins with proangiogenic factor mediated activation of matrix 
metalloprotease 9 (MMP9) in the osteoblastic zone. Once activated, MMP9 
proteolytically cleaves the membrane bound Kit ligand to its active form. Kit is a 
cytokine which causes the recruitment and release of EPC’s into the circulatory system 
(Heissig et al., 2002). Once released, EPC’s will either contribute to the creation of 
angiogenic sprouts or into endothelial monolayers via selectins and integrins (Deb et al., 
2004).  
 
Vasculogenesis’s role in tumor formation, depending on the type of tumor and cancer 
model created, ranges from 0.1 to 50% of all vessels created (Zuazo-Gaztelu & 
Casanovas, 2018). Vasculogenesis also plays a role in metastasis through stromal derived 
factor 1 (SDF1) and C-X-C chemokine receptor type 4 (CXC4). SDF1, produced by 
immune cells, could attract EPC’s to distant sites. Once there, the EPC’s would produce 
and create a gradient of SDF1 from where they originally came. Meanwhile, the CXCR4 
receptor expressed mainly by tumor cells will interact with the SDF1 secreted by EPC’s. 
This interaction promotes the extravasation of tumor cells to the SDF1 secreted gradient 
and establish a pre-metastatic niche (Jin et al., 2012). MMP9 activation via EPC’s also is 
said to increase tumor cell metastasis, linking vasculogenesis to the metastatic niche as 




Along with normal processes of vasculogenesis and sprouting genesis, malignant tumor 
cells also have a tendency to dedifferentiate and adopt multiple different phenotypes in a 
process known as vasculogenic mimicry (VM) (Figure 5). Cells that do undergo VM 
converge in vessel-like network similar to normal angiogenesis. As a result, these cells 
are able to mimic the early embryonic vascular plexus and create a tumor ecosystem with 
circulatory system independent of the one created via angiogenesis. The first known 
instance of VM was observed through studies with melanoma cells whose phenotype 
reverted to an embryonic-like state. This state featured an increase in cell plasticity, as 
well as expression of endothelium-associated genes Ephrin-A2 and VE-Cadherin 
(Hendrix et al., 2003). VM promoters include but are not limited to: the release of ECM 
components, hypoxia, and activation of transmembrane metalloproteinases (Seftor et al., 
2005).  
 
Intussuscpetion, also known as intussusceptive microvascular growth (IMG), is the 
process of splitting preexisting vessels (Figure 5). IMG has been observed in mammary, 
colorectal, and melanoma tumors (Dome et al., 2007). Links between VEGF and IMG 
were also observed in human melanomas, suggesting that inhibition of angiogenesis 
could stimulate IMG as well (Ribatti et al., 2005). Considering that IMG takes place with 
preexisting vessels only, its role in tumor growth and malignization is linked to 







Figure 5. Mechanisms in blood vessel growth in tumors. (A) Sprouting Angiogenesis 
takes place in both tumor and normal blood vessel growth. (B) Tumor vasculogenesis 
recruit’s EPC’s through MMP9 and soluble form Kit-ligand. (C) VM is the process by 
which tumor cells dedifferentiate to express varying phenotypes. (D) Intussusception, 
also known as IMG, causes the splitting of preexisting blood vessels, further increasing 
the complexity of the tumor blood vessel network. Both VM and IMG are much less 
frequently expressed in vascular formation and act simultaneously in pathological 
neovascularization. Figure taken from (Zuazo-Gaztelu & Casanovas, 2018). 
 
 
Without proper vascular development (avascular phase), a tumors potential for growth is 
limited to 1-2 mm3 (Zuazo-Gaztelu & Casanovas, 2018). In order to grow beyond such a 
projected size, a tumors vasculature needs to be extended. The process of transitioning 
from an avascular to vascular tumor through angiogenic growth is known is the 
“angiogenic switch” (Folkman, 1990). Studies have shown that without this switch, 
tumors will eventually succumb to apoptosis or necrosis, further establishing the 
importance of vasculature in tumor growth (Holmgren et al., 1995). Indeed, there is a 
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dynamic balance that dictates the probability of an angiogenic switch from taking place. 
This balance is between positive (proangiogenic) and negative (antiangiogenic) factors 
(Hanahan &Folkman 1996). Normal physiological conditions have this balance shifted 
towards the negative regulation of angiogenesis in order to maintain proper vasculature. 
Under tumor growth, mechanisms emerge which lead to inhibition of tumor suppressor 
genes and upregulation of oncogenes. This shifts the dynamic balance in the opposite 
direction towards proangiogenic factors. Examples of such factors include PDGF, 
Endothelial-Growth Factor (EGF), FGF, MMP’s, angiopoietins, and VEGF. VEGF and 
FGF, both strong angiogenic inducers, are normally released into the tumor ecosystem 
during the first steps of tumorigenesis (Zuazo-Gaztelu & Casanovas, 2018). 
  
In an attempt to avoid inhibition by ECM-associated molecules, tumor cells upregulate 
proangiogenic factors as well as downregulate expression of tumor suppressor genes such 
as p53 (Fernando et al., 2008). Furthermore, tumor cell metabolism and increased 
consumption of glucose leads to an increase in lactic acid production. This lactic acid 
build up leads to a decrease in extracellular pH (Payen et al., 2016).  
Increase lactic acid in the tumor system has also been shown to promote Epithelial-
Mesenchymal Transition (EMT) and metastases of several human cancers such as lewis 
lung carcinoma and melanoma (Suzuki et al., 2014). Increased levels of VEGF are also 
seen as a result of the acidification of the ecosystem, leading to more angiogenesis (Shi et 




The general nature of tumor masses is that they are hypoxic due to their distorted and 
abnormal vascular networks, making transportation of oxygen to tumor cells extremely 
inefficient and weak (Vaupel, 2004). Hypoxia also promotes expression of proangiogenic 
factors, as well as controlling the recruitment of immune cells to the tumor ecosystem 
(Blouw et al., 2003). Intravasation, which is characterized by the movement of cancer 
cells through the basement membrane into lymphatic or blood vessels, is also regulated 
via hypoxia indirectly through upregulated gene expression of VEGF and MMP’s (Lu & 
Kang, 2010). Apoptosis inhibition, anaerobic metabolism, increased invasiveness, EMT, 
and even metastasis are all regulated to an extent via Hypoxia as well.  
 
Although primarily used for tumor growth, Angiogenesis also plays a role in cell 
metastasis. This promotes creation of new tumor ecosystems in other locations in the 
body. This occurs through tumor EC’s using VEGF to upregulate the secretion of 
proteases. The proteases then degrade the basement membrane, making access for 
metastasis and intravasation easier. In addition, VEGF increases expression of molecules 
responsible for tumor-EC interactions, once again increasing the probability of metastasis 
(Carmeliet, 2005). Like EC’s, pericytes also promote angiogenic-driven metastatic 
processes. Pericytes connected to tumor cells and vessels are less tightly attached to 
EC’s, which increases the number of intracellular gaps. As a result, chances for tumor 





Retina: Overview, Organization and Development 
One of the biggest reasons for blinding diseases in the in the retina is due to a disrupted 
oxygen supply, which in turn leads to a loss of function of photosensitive neurons. These 
photosensitive neurons are responsible for the phototransduction of visual information 
from the retina to cognitive centers in the brain (Arjamaa & Nikinmaa, 2006). Overall, 
retinal oxygen and nutrient supply come two different vascular beds: the retinal 
vasculature and the choroid. The retinal vasculature is smaller but much more specified 
circulation, while the choroid is denser and more permeable with little to specification at 
all (Figure 6). Both vasculatures can develop issues and alterations as a result of diseases 




Figure 6. Retinal and Choroidal Vasculature. (A) Top Image showcases the entirety of 
the retinal vasculature. (B) Bottom image showcases the permeable less specified 
choroidal vasculature. Figure taken from (Chaqour & Karrasch, 2020). 
 
Using rodents as a model, retinal vasculature development begins with the growth of 
endothelial tubes from the optic nerves. This is followed by ensheathment with mural 
cells and branched growth of vascular tubes in what is known as the retinal-vitreal 
interface. This is said to take place in between postnatal day (P) 1-9. These vascular tubes 
would eventually grow into the outer plexiform layer (ONL) and inner plexiform layer 
(INL) to form the deep and intermediary capillary plexus during P7-11and P11-17 stages, 
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respectively (Figure 7). Interestingly, this angiogenic growth takes place without 
disruption of pre-existing retinal growth due to cross-talks between neural cells, glial 
cells, and newly developing blood vessels (O’Sullivan et al., 2017). The retina relies 
upon Retinal ganglion cells (RGC’s) to respond hypoxic stimuli through the regulation 
and release of proangiogenic factors which provide vasculature to an otherwise ischemic 
retina. This continues as they begin to mature into full functioning neurons and rely on 
more oxygen and nutrients for proper function (Fu et al., 2020). Another key factor that 
dictates retinal growth is between neuronal cells and ECM proteins. Growing RGC axons 
keep direct contact with the basement membrane as they begin to exit the retina and 
move towards the brain. This is done with the help of ECM proteins laminin and 
dystroglycan, which is a laminin-binding transmembrane protein (Hunter et al., 2019).  
 
Muller cells, the glial cell of the retina, also display properties that assist with retinal 
vessel formation, regeneration, and response to injury (Bringmann et al., 2006). Muller 
cells are responsible for ensheathing retinal neurons, which helps protect them against 
mechanical stress but also helps connect them with vasculature (Chaqour & Karrasch, 
2020). Muller cells fortify the vascular endothelial barrier through secretion of pigment 
epithelium-derived factor (PEDF), thrombospondin-1, and glial cell line-derived 
neurotrophic factor (Nishikiori et al., 2007). Studies showed that loss in Muller Cell 
expression in mice resulted in multiple vascular defects (Shen et al., 2012). Lastly, 
Muller cells are responsible for the secretion of matricellular protein CCN2/CTGF, which 
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is known to play a critical role in vessel development and barrier integrity (Moon et al., 
2020).    
 
Figure 7. Retinal Neural Layers and Vasculature Arrangement. A section of the 
general vasculature as well as neural layers of the retina, whose role is to properly 
transduce visual stimuli into neural impulses to be sent to the brain for higher sensory 
processing. Figure taken from (Chaqour & Karrasch, 2020). 
 
 
The Vascular ECM of the Retina 
 
The ECM of the retina plays a complex but critical role in blood vessel formation and 
function, none more important than anchoring vascular cells on the basement membrane 
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(Yurchenco et al., 2004). The basement membrane has a thickness of 20-200nm and is 
comprised of at least 20 ECM proteins (Yurchenco, 2011). In order for proper vascular 
growth, the basement membrane relies upon four major glycoprotein families: laminins, 
collagen IV, nidogens, and heparan sulfate proteoglycan (HSPG) (Chaqour & Karrasch, 
2020). Together, these proteins provide integrity, growth, and function to the developing 
vasculature surrounding the retina to ensure proper oxygen and nutrients flow to areas of 
need (Figure 8). 
 
Type IV collagen molecules consist of two α1 and α2 subunits, and form a branched 
network that is comprised of NC1 and 7S domains. Reduction or Knockout of the type IV 
collage subunit gene reduced stability and caused increased embryonic lethality in mice 
(Pöschl et al., 2004). Overall knockout of type IV collagen lead to destabilization in 
capillary walls as well neural defects in central nervous system microvasculature. (Gould 
et al., 2005). Likewise, laminins also play a critical role in vascular growth and integrity. 
Laminins are comprised of 5 α-chains, 4 β-chains, and 3 γ-chains. Again, loss of function 
of particular chains lead to a permeable and weakened vasculature, causing hemorrhage 
in the central nervous system microvasculature as well as embryonic lethality 
(Yurchenco, 2011).   
Normally, laminin-collagen IV networks are connected via nidogen and HSPG’s 
(Thomsen et al., 2017). Nidogen-1 and 2 are located in retinal vasculature, specifically in 
vascular and Bruch’s membranes (Kunze et al., 2010). Similar to laminin and collagen 
IV, disruption in the activity of nidogen results in destabilization and malfunction in the 
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integrity and development of the retinal vasculature. Loss of function of nidogen-1 and 2 
in mice result a lethal phenotype at bitch, showcasing the importance of maintaining a 
properly stable laminin-collagen network (Bader et al., 2005). Similarly, HSPG’s 
stabilize the vascular basement membrane through affinity to growth factors such as 
FGF, transforming growth factor beta (TGF-β), glial-derived neurotrophic factor, and 
VEGF (Vempati et al., 2011).  
 
Smaller proteins such as fibulin-1, fibulin-2, thrombospondin-1, secreted protein acidic 
and rich in cysteine (SPARC), tenascins, and CCN family proteins also play a role in 
maintaining proper cell-ECM interactions (Halfter et al., 1998). Loss of function with 
certain smaller proteins previously mentioned showcased a particularly weak response to 
ischemia or diabetes, implying that these proteins play a role more in tissue remodeling 
and repair rather than integrity and function (Praidou et al., 2010). One set of proteins in 
particular that have provided newfound understanding with regards to tissue repair and 
remodeling has been the CCN proteins, particularly CCN1/CYR61 and CCN2/CTGF.  
Instead of acting in a structure role for the ECM, these proteins provide signals which 
modify cellular responses in response to the changing environment. Such signals are 
normally present in microvascular diseases and are closely linked with blood vessel 




Figure 8. Components of the Subendothelial ECM. The ECM is comprised of 4 main 
glycoprotein families: laminins, collagen IV, nidogens, and HSPG’s. There are also other 
components such as integrins and fibronectins that play a role in cell-cell adhesion. 
Lastly, cell signaling molecules that can alter expression levels in cells as a result of 




CCN2/CTGF Configuration and Activity   
 
CCN2 (or CTGF) is a member of the CCN family of matricellular proteins (Hall-Glen & 
Lyons, 2011). Although CCN2 has been studied as the possible signaling protein in a 
variety of ECM fibrotic diseases, CCN2 and its counterpart family members are 
expressed during development, cell-adhesion, proliferation, survival, and even migration. 
CCN2 has also been shown to play a critical role in blood vessel formation and 
regeneration, making it a key player in possible pathological neovascularization and 
angiogenesis (Chaqour, 2020). 
 
The CCN family is comprised of 6 proteins: CCN1/Cy61, CCN3/Nov, CCN4/ WISP-
1/ELM1, CCN5/WISP-2/CTGF-L and CCN6/WISP-3. They are all cysteine-rich 
matricellular proteins with an N-terminal secretory peptide, as well as four conserved 
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domains (Figure 9) with sequence homologies to: insulin-like growth factor binding 
protein (IGFBP), von Willebrand factor type C repeat (vWC), thrombospondin type I 
repeat (TSP1), and lastly a carboxy-terminal (CT) domain which contains a cysteine-knot 
binding motif (Chaqour & Karrasch, 2020). The primary structure includes 38 cysteine 
residues which are conserved in position and number in 5 out of the 6 members of the 
CCN family (Chaqour & Karrasch, 2020). 
  
Figure 9. Domain Structure and 3D Domain of CCN2. The Structure of the CCN2 
protein begins with a N-terminal secretory peptide, followed by 4 domains: IGFBP, 
vWC, TSP1, and CT. The diagram to above to the left includes molecules who interact 
with each specific domain. The Diagram to the right showcases the 3D structure of the 
protein. Figure taken from (Chaqour & Karrasch, 2020). 
 
 
Each domain of CCN2 is known for interacting with particular molecules that lead to 
modifications in gene expression. The vWC domain is known for mediating CCN2 
interactions between integrin proteins ανβ3 and ανβ5, as well as growth factors such as 
bone morphogenic protein (BMP) and TGBβ (Leu et al., 2002). vWC and IGFBP have 
been shown to bind to aggrecan, a proteoglycan produced by chondrocytes (Aoyama et 
al., 2009). TSP is known for binding with MMP’s and integrins, mediating interactions of 
CCN2 with VEGF and lipoprotein-receptor related protein 1 (LRP1) (Hashimoto et al., 
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2002). Lastly, the CT motif contains a cysteine knot which is used as means of 
interacting with multiple growth factors such as TGFβ, PDGF, and nerve growth factor 
(NGF) (Hall-Glen & Lyons, 2011). Overall, these domains are what promote interactions 
and cause changes in gene expression on cell proliferation, survival, differentiation, 
migration, adhesion, and ECM production (Leak, 2006).  
 
CCN1/Cyr61 Configuration and Activity 
CCN1 (Cyr61) is cysteine rich protein part of the larger CCN protein family (6 in total as 
previously mentioned). During embryogenesis, the CCN1 gene is said to play a role in 
cardiovascular development (Mo et al. 2002; Mo & Lau 2006). In adulthood, CC1 
expression is associated with inflammation and tissue repair (Lau, 2011). While studies 
have shown that CCN2 expression levels (along with other CCN family proteins) were 
elevated in tissue injury and pathologies such as fibrosis and cancer (Jun & Lau, 2011), 
other findings have showcased that CCN1 plays roles in injury repair of organs and 
tissues (Kim et al., 2018). 
Wound healing and injury repair, occurs in three overlapping but distinct phases: 
infiltration, proliferation, and remodeling. Infiltration begins during the inflammatory 
phase, where neutrophils and macrophages invade the initial site of injury to remove 
microbes and cell debris. Next comes the proliferation phase, where myofibroblasts being 
to construct ECM. This ECM construction is created in order to promote integrity of 
tissues as well as parenchymal cell proliferation. Lastly, the newly created ECM is 
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remodeled in order to emulate the composition of the region prior to injury. (Kim et al., 
2018). CCN1 is said to regulate each of these steps through interactions with specific 
integrin receptors (Lau, 2016). In fact, CCN1 binds integrins ανβ3 and ανβ5 in epithelial 
cells and α6β1 in fibroblastic cells (Leu et al., 2003; Chen et al., 2004; Leu et al., 2004). 
Similar to CCN2, CCN1 contains a similarly conserved gene sequence by which a variety 
of integrins bind into (Figure 10).  
 
Figure 10. Domain Structure of CCN1. Similar to CCN2, CCN1 contains an N-
terminal secretory peptide, as well as 4 structural domains which are conserve in the 
CCN family. Certain lines showcased represent the binding sites of integrins with the 
specific name shown above. vWC contains binding sites for integrins ανβ3 and ανβ5, 
TSR for integrin α6β1, and lastly CT domain contains two α6β1 binding sites as well as 
an αΜβ2 site (Leu et al., 2004; Schober et al., 2002). TSR also can bind 
phosphatidylserine as well (Jun et al., 2015). Figure taken from (Kim et al., 2018). 
 
Through binding to integrin ανβ3 in EC’s, CCN1 can induce angiogenesis (Babic et al., 
1998; Leu et al., 2002). As previously stated, EC’s of angiogenic sprouts are organized 
into tip cell and stalk cells through a Dll4-Notch Signaling pathway orchestrated through 
the secretion of VEGF (Phng & Gerhardt, 2009). CCN1 is said to regulate Dll4 
expression and Dll4-Notch signaling between the tip and stalk cells. They also regulate 




This thesis will dive into research on the roles that proteins CCN1 and CCN2 have on the 
process of angiogenesis and neovascularization. Possible therapies that could be used to 
target and treat pathological diseases linked to mechanistic pathways of angiogenesis via 
the CCN1 and 2, such as blinding diseases and tumor growth, will be discussed as well.  
Specific Aims 
Specifics of the following thesis include:  
1. Comprehensive review of literature to determine the active roles of CCN1 and 
CCN2 proteins in the mechanistic pathways of blood vessel growth 
2. The effects that knockouts and over-expressions on specific proteins related to 
CCN1 and CCN2 (as well as themselves) have on blood vessel vasculature  
3. The direction that research and therapies will have on blood vessel growth linked 








CCN1 and Associated Proteins 
CCN1 and its Role in Angiogenesis  
 Matricellular protein CCN1 has been shown to play a role in proper 
cardiovascular development as well as promoting wound healing and tissue repair. 
However, recent studies have shown that CCN1 has a remarkable impact on 
angiogenesis, particularly in retinal neovascularization. This section will provide studies 
that further attempt to discover CCN1’s role in such angiogenic processes, as well as 
detail the effects that gene over-expressions and knockouts of CNN1 and other proteins 
have on blood vessel growth.  
CCN1 & Micro(miRNA)-155 
Etiological origins of numerous “blinding diseases” have been said to occur from the 
high metabolic and oxygen demands of the neural retina. (Tolentino, 2019; Yan & 
Chaqour, 2013). Conditions such as diabetes, trauma, hyperoxia, aging, dyslipidemia, and 
even environmental insults can lead to possible vascular bed injury, causing issues in 
normal vascular flow and decrease in proper nutrient’s and oxygen to tissues in the retina 
(Lulu et al., 2015). Issues in normal vascular flow can be seen in the form of blood vessel 
damage or even overall stoppage of vascular development. This then causes pathological 
development of disorganized and permeable vessels to form, which causes fluid to leak 
out of the vasculature and into the vitreous of retina and causing hemorrhage, retinal 
detachment, and of course vision loss (Lulu et al., 2015). Micro(miRNA)-155 is a pro-
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inflammatory small RNA that plays a functionally important role in inflammation (Lulu 
et al., 2015). miRNA-155 has also been shown to influence pathological retinal 
neovascularization through ties to CCN1. These ties are what prompted studies to be 
conducted in an attempt to determine possible effects that miRNA-155 has on CCN1.  
Using a mouse model known as oxygen induced retinopathy (OIR), researchers were able 
to develop a proper neovascularization model. OIR begins with neonatal mice being 
exposed to 75 percent oxygen in a chamber at the P7-12 stages of development. This 
leads to vaso-obliteration and the hindering of blood vessel development in the capillary 
beds of the retina. At P12, the mice are then placed in normal air to P17. At this point, the 
mice are put through CO2 euthanasia in order to allow for proper dissection of the retina 
as means of analyzing maximum neovascular response (Lulu et al., 2015).  This model 
allowed for the expression of pathology-like phenotypes in an effort to determine if there 
was any genotypical change through analysis of miRNAs.  
Following OIR, the mice retinas were harvested and real time PCR was performed as a 
means of comparing expression levels of several mi-RNA’s. Overall, some mi-RNA’s 
were differentially expressed at the P12 stage following the hyperoxia-induced vaso-
obliteration, such as miR-103, miR-107, miR-125, miR-127, miR-93, miR-16, miR-195, 
and of course miR-155 (Table 1). In addition, results showed that miR-155 increased 
during both the P12 hyperoxia stage as well as the P17 “ischemic” stage of normal 
oxygen levels. In both stages, miR-155 levels were increased by nearly 2 and 4-fold, 
respectively, as compared to normal oxygen levels. Overall, miR-155 levels were 
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upregulated during changes in oxygen levels which lead to abnormal vascular growth and 
neovascularization. (Figure 11).  
       
Table 1. Changes in Expression levels of miRNA’s in Retina following OIR. 
MicroRNA that was analyzed via real time PCR. The data was filtered via fold changes 
>2 and <-2 as well as a p <0.05 to maintain statistical significance. It should be noted that 
miR-155 displayed a large log2 of 5.8706, a remarkable upregulation in expression 




Figure 11. miR-155 Expression Levels. Mice were placed at 75 percent oxygen starting 
from P7 up to P12 (OIR). The mice were then removed from the hyperoxia environment 
and left at normal oxygen conditions till P17, where the mice were euthanized and 
harvested. miR-155 levels were stagnant during normal control levels, but through OIR 
induced hyperoxia and normoxia “ischemic”-like conditions, miR-155 transcription 
levels were upregulated from P7 onward. Taken from (Lulu et al., 2015). 
In order further understand the role of miR-155 in retinal vasculature, the same OIR 
mechanism was carried on with a miR-155 -/- mice. In both the wild type and the miR-
155 mice, OIR from P7-P12 lead to vaso-obliteration of the central superficial capillary 
plexus as well as nearly 32% decrease in retinal surface area (Figure 12). However, miR-
155 -/- mice showcased much greater neovascularization during the P17 normoxic phase 
than did the wild type (Figure 12). In addition, more than 95% of the retinal surface was 
vascularized in the miR-155 -/- mice versus 87% for the wild-type mice (Figure 12). 
Retinal vasculature also varied between the wilt type and miR-155 -/-, with much lower 
levels of neovascular tufts present in the miR-155 -/- than the wildtype (Figure 12). This 
furthered the assumption that the miR-155 deficient mice were able to prevent 
development of random neovascularization post OIR (P17 onwards), although the same 




Figure 12. Wildtype versus miR-155 deletion during and post-OIR. (A) Comparisons 
between vaso-obliteration of vessels at P12 (right after OIR is stopped) between wildtype 
and miR-155 -/- in yellow are shown. (B) Lower levels of neovascular tuft formation (in 
blue) and vaso-obliteration (yellow) were present at P17 post normoxia in miR-155 -/- 
levels than in the wildtype. (C) Avascular area as a percent at P12 presented similar 
levels of loss for both the wildtype and miR-155 -/-. (D) Avascular area as a percent at 
P17 showcased a significant difference between wildtype and miR-155 -/-. miR-155 -/- 
levels were much lower than its wildtype counterpart, giving possibility that lack of miR-
155 allowed for further revascularization. (E) Neovascular tuft formation, a usual sign of 
aberrant vascular growth, was much lower in miR-155 depleted mice than the wildtype at 




Studies were then conducted with miR-155 deficient mice to analyze more of the 
vasculature. A decrease in junctional density and increase in vascular length more than 
40% was exhibited by miR-155 deficient mice in comparison to the wildtype (Lulu et al., 
2015). Intravitreous injection of miR-155 mimic during the P3 stage of superficial 
capillary plexus was conducted to see the potential impact of miR-155 during the growth 
stage of retinal vasculature. In comparison to the scrambled miRNA, the miR-155 
injected mice showcased reached only 59% of the distance to the retinal edge, in 
comparison to 80% in the controlled scramble miRNA (Figure 13). In addition, the 
mimic miR-155 mice displayed a 65% percent increase in endothelial cell proliferation in 
comparison to a 20% decrease in miR-155 deficient mice (both were compared to the 
control) (Figure 13).  From these findings, it could be stated that miR-155 was able to 








Figure 13. Control, mimic miR-155 injection, and miR-155 -/-. (A) P7 stage growth in 
retinal vasculature in comparison to the retinal edge, seen in the white line. The second 
line to the left represents the growth of the control and miR-155 injected vessels, 
respectively. (B) Retinal advancement and retinal radial growth were significantly 
decreased in mimic-injected miR-155 mice than for the control. (C) Overlapping growth 
between astrocytes and endothelial cells between both control and miR-155 showcased 
no potential influence of astrocytes via miR-155. (D) Effects of miR-155 gain or loss of 
function when compared to the control. (E) Bromo-2-deoxyuridine (BrdU) incorporation 
was performed to measure levels of proliferation between control, miR-155 injected and 
miR-155 deficient mouse retinas. Injection of mimic-miR-155 did in fact lead to an 
increase in endothelial cell proliferation in comparison to miR-155 -/- and the controls. 
Taken from (Lulu et al., 2015). 
Target genes were established in order to identify the potential influence that miR-155 
has in angiogenic processes of physiological development and pathology. One of the 
target genes was evidently CCN1, the matricellular protein known for playing a 
substantial role in the signaling pathways that regulate blood vessel growth. In order to 
determine a possible relationship between the two, miR-155 mimic was injected at P4 
during the live angiogenic process. Increases through the miR-155 mimic lead to 
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significant decreases in CCN1 mRNA and protein levels. However, miR-155 -/- cells saw 
CCN1 levels rose to remarkable levels at P12 and P17 post-OIR respectively (Lulu et al., 
2015). This growth in CCN1 levels in the miR-155 -/- retina was further tested with the 
usage of a mutant form of the CCN1 protein which inhibits activity (Choi et al., 2013). 
Overall, the CCN1 mutant lead to an increase in OIR-induced neovascularization of 
nearly 48% when compared to the control. Furthermore, there were higher levels of 
avascular area in the mutant CCN1 mice than the controls (Lulu et al., 2015). 
In order to determine if miR-155 directly inhibits or reversibly expresses CCN1 
expression, the 3’ untranslated region (UTR) of CCN1 was first cloned into a reporter 
plasmid vector and expression levels of CCN1 were measured following alterations to the 
UTR (Figure 14). These alterations were conducted using the help of a Target Scan 
algorithm, which showcased that the 3’-UTR of CCN1 contained conserved sequences 
for 7-8 miRNA’s, such as miR-155, miR-22, miR-181, and miR-221 (Figure 14). 
Through the algorithm, mutations were conducted that influenced the supposed binding 
region of miR-155. These mutations, located in the proximal region of the UTR, reduced 
the repressive effects that were previously displayed in the normal UTR by 76% (Figure 
14). Thus, removal of the miR-155 binding region in CCN1 lead to a reversal in 




Figure 14. CCN1 Expression Levels via 3’UTR. (A) The CCN1 3’UTR contains 
binding regions for mi-RNA’s including miR-155 located near base 110 of the 690-base 
total. (B) The plasmids by which the endothelial cells were transfected with. The U690 
(top) represents the full 3’UTR whereas the MT05 (bottom) represents the complete lack 
of one. (C) Luciferase Activity, the method utilized to measure CCN1activity, was 
remarkably higher in the MT05 versus the U690. (D) Mutations to the miR-155 region in 
the 3’UTR (more proximal than distal) lead to a reduction in the repression previously 
seen via the fully expressed U690 UTR. Figure taken from (Lulu et al., 2015). 
 
Such a relationship between CCN1 and miR-155 prompted the creation of an inducible 
knockout of the CCN1 gene in order to determine if the angiogenic process seen in 
upregulated miR-155 on CCN1 could be emulated. The reason for an inducible knockout 
rather than constitutive inactivation stems from studies which showed that permanent 
inactivation of CCN1 from development leads to embryonic lethality (Mo et al., 2002). 
After showcasing proper knockout of CCN1 through substantially decreased mRNA 
levels, images were taken of the vasculature that showcased much different blood vessel 
growth morphology than the normal CCN1. Overall, the mutant CCN1 mice had much 
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larger levels of junctional density with much smaller total vessel length (Figure 15A-B). 
In an effort to determine whether miR-155 could impact the development of blood vessel 
growth, mice were created to have a double knockout of miR-155 and CCN1. The double 
knockout miR-155-CCN1 cells displayed widened blood vessels, increased vascularity, 
and decreased permeability, all of which were very similar to the CCN1 singular 
knockout (Figure 15 C-D). Thus, CCN1 knockouts and CCN1-miR-155 knockouts were 
able to properly mimic the morphology of an miR-155 gain of function (Lulu et al., 
2015). 
 
Figure 15. CCN1 inducible knockout morphology and quantitative analysis. (A) 
Measurement of junctional density of CCN1 -/- and miR-155/CCN1 double knockout 
against normal CCN1 control. (B) Total Vessel length CCN1 -/- and miR-155/CCN1 
double knockout against normal CCN1 control. (C and D) Morphology of the double 
knockout against the CCN1 knockout. Similar morphology supported with data of 





CCN1 and Yes Associated Protein (YAP)  
YAP is a transcriptional coactivator that regulates cell growth and organ size through the 
hippo pathway (Zhang et al., 2011). Activation of YAP is controlled through 
phosphorylation, which sequesters the coactivator into the cytoplasm for inhibition 
(Plouffe et al., 2015). Meanwhile, deactivation through removal of the phosphate group 
leads to YAP translocating into the nucleus, where it will interact with DNA-binding 
transcription factors such as serum response factor (SRF) and transcriptional enhanced 
associate domain (TEAD) (Yu et al., 2013). Normally, what regulates YAP activation or 
deactivation usually include processes such as cell-cell adhesion, cell-cell interactions, 
and cell polarity. Such processes are also closely related to blood vessel growth and 
angiogenesis (Chaqour, 2013). CCN1, a prominent signaling protein in blood vessel 
growth, has been suggested as a target of YAP, as YAP deletion presented similar 
morphology in terms of vascular defects to a CCN1 deficiency in mice (Mo et al., 2006). 
Using green fluorescent protein (GFP) as a marker, YAP and CCN1 expression levels 
were mapped across the mouse retina (retinas as stated previously are utilized to study 
proper blood vessel development and growth). Overall, the GFP-CCN1 levels were 
visualized predominantly in “tip cell” EC’s. In fact, such GFP fluorescence was nearly 
four times stronger in the vascular “tip cell” front than the central zone (Figure 16). 
Meanwhile, YAP-GFP displayed a uniform distributed signal throughout the developing 
capillary plexus (Figure 16). Its presence in the nucleus, normally a sign of activation for 
YAP, could be seen in the advancing front. However, fully developed vasculature 




Figure 16. Expression levels for CCN1 and YAP in Mouse Retina. (A) Expression 
levels of CCN1 and YAP showcased through fluorescence via GFP. (B) Using GFP 
fluorescent signaling, central and peripheral zones were measured to display the strength 
of signal between CCN1 and YAP. (C) Central and Peripheral zones measured according 
to strength of YAP and CCN1. Taken from (Lee et al., 2019). 
Connections linking CCN1 to YAP were showcased through transfection experiments 
using luciferase reporter gene on the CCN1 promoter fragment (Lee et al., 2019). Known 
for being transcriptionally activated through Rho-GTPase and globular actin 
concentration (Hannah et al., 2009), CCN1 expression levels were measured with DNA-
binding proteins that were linked to actin dynamics as well as YAP. YAP interacts with 
DNA-binding partner TEAD which contains promoter regions on CCN1. Overall, 
increases in CCN1 levels lead to decreases in YAP phosphorylation via the TEAD 
proximal binding site on CCN1 (Figure 17). Increases in CCN1 levels were caused via 
jasplakinolide, which is a naturally occurring molecule which induces actin 




Figure 17. Expression of CCN1 causes decrease in phosphorylated YAP. 
Jasplakinolide upregulated expression of signaling pathways directly linked to CCN1 as 
well as YAP via actin polymerization and dynamics. This caused an increase in CCN1 
levels as well as decreased in the inactive form of phosphorylated YAP. GAPDH was 
used as the control in this context. Taken from (Lee et al., 2019). 
In order to prove that YAP activation is a primary determining factor in CCN1 activation 
in EC’s, mice were generated that contained an EC-specific or ubiquitous deletion of 
YAP (Figure 18). Although no vascular defects were present in the EC specific YAP, the 
ubiquitous YAP exhibited decreases in cell proliferation, vascular area, junctional 
density, and radial expansion of vasculature when compared to its YAP wildtype and EC-




Figure 18. YAP-dependence for activation of CCN1. (A) Creation of a transgenic 
modified EC-specific and Ubiquitous YAP. (B) EC-specific modifications YAP lead to 
decreases in overall YAP enrichment. (C) Ubiquitous modifications to YAP lead to a 
decrease in overall YAP enrichment as well. (D) Vascular area was significantly reduced 
with Ubiquitous YAP, yet not for EC-specific YAP. (E) Although branching was 
significantly decreased in both EC-specific and ubiquitous YAP when compared to 
wildtype, ubiquitous YAP displayed much lower levels than the EC-specific YAP. (F) 
BrdU levels were substantially lower for Ubiquitous YAP and EC-specific YAP when 
compared to controls. Taken from (Lee et al., 2019). 
Genotypically, YAP-TEAD is known for upregulation of pathways involved in cell 
proliferation and EC differentiation. Such pathways normally include genes that play 
roles in cytoskeleton remodeling, cell adhesion, ECM remodeling, and VEG-VEGFR2 
signaling (Wang et al., 2017). Through quantitative PCR analysis, expression levels of 
genes that played a role in previously the mentioned pathways were analyzed in both 
Ubiquitous deletion and EC-specific deletion of YAP mutant retinas. (Figure 19). In 
comparison to the wildtype YAP, Ubiquitous deletion of YAP caused a reduction in 
cytoskeletal, ECM, VEGF signaling, and cell cycle genes by more than 50%. Meanwhile, 
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EC specific deletion of YAP caused a less than 50 % reduction, hinting that EC specific 
YAP is not a larger global driver of change in vessel growth than ubiquitously expressed 
YAP.  
 
Figure 19. YAP mutations effects on downstream gene expression levels. (A-E) 
Representation of cytoskeletal, ECM, VEGF signaling, and cell cycle genes and their 
expression levels in EC and Ubiquitous deletion of YAP. Overall, Ubiquitous YAP 
showcased more decreased in expression, but overall both mutant YAP saw decreases in 
gene expression with most of the presented genes except for VEGF-A and VEGF-R2. 
Taken from (Lee et al., 2019).  
 
In an effort to understand the potential feedback loop association between YAP and 
CCN1, overexpression of CCN1 via an adenovirus mediated transfection performed. If 
such a loop did exist, then increases or decreases in YAP would follow the large surge in 
CCN1 expression levels. Analysis of Human Retinal EC cultures following adenovirus-
mediated CCN1 overexpression displayed increased levels of Phosphorylated 
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(inactivated) YAP (Figure 20). Furthermore, GFP-tagged YAP was noticed to have a 
larger presence in the cytoplasm during enriched CCN1 levels as oppose to YAP in the 
nucleus with lesser CCN1 levels (Figure 20). 
 The effects of VEGF on YAP were also studied in cohesion with CCN1 levels as VEGF 
is a known activator of YAP (Wang et al., 2017). Such studies were proven to be true as 
VEGF-stimulated cells did lead to increases in non-phosphorylated YAP. However, 
decreases in active-YAP was observed upon addition of CCN1 with VEGF (Figure 20). 
In fact, in the VEGF-stimulated cells, addition of high levels of CCN1 lead to a decrease 
in YAP-TEAD activity by nearly 80% (Figure 20).  Such a connection between VEGF 
and CCN1 prompted research to be conducted on the integrin receptors of the CCN1 
ligand. Through function-blocking integrin antibodies, various integrin receptors were 
inhibited while still containing adenovirus-infused CCN1 and VEGF. Results showed 
that blockade of either β1, β3, or αvβ3 integrin rescued VEGF-induced YAP 





Figure 20. CCN1 expression controls YAP expression via a signaling loop. (A) 
Increasing expression levels of CCN1 cause decreases in the phosphorylated(inactive)-
YAP to YAP (active) ratio. (B) Presence of YAP in the cytoplasm increases through the 
addition of overexpressed CCN1 and increases in the nucleus during lower levels as 
exemplified though a YAP-GFP. (C-E) VEGF expression assists in mitigating 
deactivation of YAP through CCN1. (F) Specific integrin inhibition via antibody blockers 
leads to decreased levels of phosphorylated YAP in the presence of both overexpressed 
CCN1 and VEGF. Taken from (Lee et al., 2019). 
Since overexpression of CCN1 resulted in a downregulated expression of YAP, loss of 
CCN1 should promote the opposite. This hypothesis was tested via EC-specific deletion 
of CCN1 in the retains of mice. After proof of decreased CCN1 expression in the EC’s, 
analysis was performed on YAP expression as well as the morphology of the growing 
retinal vasculature. Phosphorylated YAP levels were decreased (Figure 21), further 
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proving the previously described YAP-CCN1 feedback loop. Morphologically, the 
vasculature of the CCN1 mutant EC’s showcased reduced forward progression and radial 
expansion (Figure 21). Furthermore, there was a loss is vascular specification in terms of 
artery, capillary, and vein differentiation. Meanwhile, the wildtype CCN1 EC’s displayed 
a slender and well-organized vasculature, as well as fully differentiated vessels (Figure 
21). Further analysis into the mutant CCN1 EC’s showed that they possessed decreased 
vascular area yet the wider vessels promoted decreased gaps between vascular branches. 
Most importantly, images revealed that mutant CCN1 EC’s possessed higher levels of tip 
cells and increased levels of proliferation. Lastly, downstream targets of YAP (these 
genes represent pathways and processes previously mentioned in this section) were 
shown to increase based off mRNA levels comparing the mutant and wildtype CCN1 
EC’s (Figure 21). From this evidence and data, it was concluded that CCN1 does in fact 
control expression of YAP through and overexpression feedback loop as well as detail 












Figure 21. EC-Specific Deletion of CCN1 promotes YAP overexpression and 
vascular growth. (A) Creation of the EC-specific deletion of CCN1. (B) Drop off in 
CCN1 transcription level in the deleted CCN1 in comparison to wildtype CCN1. (C) 
CCN1 levels were markedly smaller in the mutant EC’s, not to mention a decrease in 
phosphorylated YAP. GAPDH was used as a control. (D) Higher levels of YAP and 
lower levels of phosphorylated YAP were noticed in the EC-mutant, whereas the 
wildtype CCN1 possessed equal levels of both YAP and phosphorylated YAP. (E-F) 
Mutant CCN1 EC’s displayed wider, shorter, and less differentiated than wildtype CCN1. 
(G-H) Vascular area and Junctional space decreased remarkably in mutant CCN1 EC’s 
when compared to wildtype CCN1. (I-K) Number of tip cells was higher in mutant CCN1 
EC’s than wildtype CCN1, as well as higher levels of proliferation. (L) Deletion of CCN1 
promoted not only an increase in YAP expression, but also an upregulation in 
downstream YAP targets affiliated with the actin cytoskeleton, actin dynamics, cell 
motility, cell growth, and VEGF signaling. Taken from (Lee et al., 2019). 
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As previously mentioned evidence would suggest, YAP expression was shown to control 
expression levels of downstream actin and cytoskeletal dynamics. YAP also promotes 
increased levels of proliferation and tuft formation with the removal of CCN1. This 
advocates the idea that the YAP-CCN1 feedback loop could possibly play a role in 
pathological angiogenesis. This was tested using OIR as a means of mimicking 
pathological neovascularization that many “blinding diseases” in the retina are associated 
with (Lee et al., 2019). Following OIR, adenovirus associated injection were performed 
in order to determine if they could rescue pathological phenotype (caused by OIR). 
Adenovirus injections included CCN1 and a dominant negative mutant YAP unable to 
interact with its DNA binding partner TEAD (Lee et al., 2019). Post transfection, it was 
clear that ectopic CCN1 expression influenced cell proliferation and neovascularization 
of tufts through an increase in phosphorylation of YAP (Lee et al., 2019). Meanwhile, the 
dominant-negative YAP decreased both CCN1 expression levels as well as neovascular 
growth in the retina. Both infections further the hypothesis that the CCN1-YAP feedback 
loop plays a role in VEGF stimulated angiogenesis as well as possible pathological 
neovascularization. Such data and illustrative evidence caused the development of 
schematic models which demonstrated the regulatory and mechanistic influences between 







Figure 22. Model of the CCN1-YAP feedback loop. A negative feedback loop through 
actin dynamics caused by VEGF leads to an active unphosphorylated form of YAP, 
which when combined with TEAD and other DNA-binding proteins leads to the 
upregulation and expression of CCN1 protein. However, overexpression of CCN1 causes 
upregulation of downstream pathways which eventually phosphorylates YAP 
(inactivation). Taken from (Lee et al., 2019). 
CCN2 and Associated Proteins 
CCN2 and its role in Angiogenesis 
CCN2, also known as CTGF, is a matricellular protein known for playing roles in 
numerous forms of fibroproliferative diseases. Such diseases normally occur through 
increases in neovascularization and blood vessel growth as a result of preexisting health 
conditions and changes in oxygen homeostasis. Studies have shown connections between 
CCN2 and cell adhesion, proliferation, migration, differentiation and ECM synthesis 
(Moon et al., 2020). This section will provide studies that further attempt to discover 
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CCN2’s role in such angiogenic processes, as well as detail the effects that gene over-
expressions and knockouts of CCN2 and other proteins have on blood vessel growth. 
 CCN2 & YAP  
Much like with CCN1, CCN2 (CTGF) has been shown to interact with numerous 
downstream regulators of angiogenesis and blood vessel growth. One such protein is 
YAP, which was previously shown to be affiliated with CCN1 in a feedback loop 
mechanism in cohesion with actin and cytoskeletal dynamics (Lee et al., 2019). To 
further grasp the role of CCN1 in angiogenesis as well as YAP’s influence, research was 
directed on the protein’s location and expression levels when overexpressed and 
deficient. These changes in expression levels caused changes in morphological 
vasculature further supporting the important role that both CCN1 and YAP have in 
angiogenesis (Moon et al., 2020).  
Studies performed using mouse retinas as models displayed strong CCN2 expression 
during retinal vessel development, but later plateauing in adult life. These expression 
levels were located in EC’s of the sprouting capillary plexus, specifically in the trailing 
stalk cells right behind the tip cells (Figure 23).  Such evidence provides the possibility 





Figure 23. CCN2 cellular localizations and expression levels during development. 
(A) mRNA levels of CCN2 (CTGF) begin to increase progressively. (B) CCN2/CTGF 
levels peak into adult life. (C) CCN2 protein levels mimic mRNA levels in that they peak 
in development and depress slightly into adulthood. (D) Cellular locations of CCN2 
through development using GFP to visualize the protein. (E) CCN2 present in EC’s of the 
primary capillary plexus. (F) CCN2 is located in trailing stalk cells, which provides 





Global, EC-specific, and pericyte-specific loss of CCN2 were studied in order to 
determine if certain cell types created pathological phenotypes associated with the retina. 
Global loss of CCN2 lead to a significant reduction of microvessel density, vascular 
branching, and vascular area. A decrease in angiogenesis was also observed as there were 
decreases in proliferation by 45%. EC-specific deletion of CCN2 lead to very similar 
morphological phenotypes to the global CCN2 loss, but the mutation produced more 
milder results. However, both the global and EC specific loss of CCN2 cells exhibited 
extensive vascular leakage when compared to wildtype CCN2 expressed cells. This was 
showcased by an increase in fluorescence in the extravascular space as oppose to inside 
the vasculature (Figure 24). In fact, vascular leakage in mutant CCN2 was 41% higher 
when compared to the wildtype (Moon et al., 2020).  Meanwhile, pericyte specific loss of 








Figure 24. Global and EC-specific deletion of CCN2 promotes vascular leakage in 
developing mouse retina. (A) Expression of normal CCN2 can be seen in panels a and 
b, which showcases very little fluorescence outside of the formed vasculature. Albumin 
connected to a fluorophore was used to test permeability of vasculature with the 
extravascular space as they are normally too large to exit said vasculature.   Panels c 
through h, which represent various mutants of CCN2, can be seen as having fluorescence 
outside of the formed vasculature as a result of a probable leaky vessels. Taken from 
(Moon et al., 2020). 
Establishment of CCN2’s influence on vascular integrity and presence in EC stalk cells 
allowed for further connections between the ECM protein and other signaling pathways 
that control and regulate blood vessel growth. Using RNA-sequence data, gene set 
enrichment analysis (GSEA) was performed in order to determine which sets of genes 
and pathways are upregulated and downregulated when CCN2 is expressed as well as 
mutated (Subramanian et al., 2005). Overall, 209 significantly altered genes (133 
downregulated and 76 upregulated) were detected when comparing wildtype and globally 
deleted CCN2 respectively. (Moon et al., 2020). Next, the RNA-sequence was compared 
to the GSEA molecular signature database, which compared experimental data to 1454 
gene sets organized into pathways and cell processes. Importantly, transcriptional 
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regulatory genes such as YAP, TEAD, and SRF were found to be downregulated upon 
loss of CCN2 function (Moon et al., 2020). However, YAP was deemed to be the most 
important of the discovered transcriptional regulators influenced by CCN2 deletion due 
to its role in the VEGF-VEGFR2 signaling axis that controls angiogenesis (Wang et al., 
2017).  
To further understand the role of YAP in CCN2 regulation of angiogenesis, GSEA was 
conducted comparing the changes in gene expression in CCN2 deletion with YAP 
overexpression. (Moon et al., 2020). What was discovered was that numerous genes that 
were upregulated in overexpressed YAP gene set, were downregulated in the CCN2 
deleted gene set. Concurrently, the same genes that were downregulated from YAP gene 
set were upregulated in CCN2 deleted gene set (Moon et al., 2020). This prompted a final 
test of quantitative PCR using YAP target genes to measure mRNA levels between 
wildtype and CCN2 deleted data sets. Of the 11 target genes selected, 9 displayed RNA-
sequence profiles and trends that were statistically significant, presenting the probability 







Figure 25. CCN2 wildtype and deleted expression profile and relation to YAP. (A-B) 
Heatmaps showcasing the top enriched YAP signature genes using GSEA between 
wildtype and deleted CCN2 gene sets. (C-D) Enrichment score comparisons of YAP 
pathway genes between wildtype and delete CCN2 gene sets. C compares what is 
enriched in the wildtype CCN2 gene sets against the deleted CCN2 gene set. D illustrates 
enrichment levels in the deleted CCN2 gene sets against the wildtype CCN2 gene set. (E) 
mRNA levels of YAP target genes between the deleted CCN2 gene set and the 




The influence of YAP in the function and regulation of CCN2 was also illustrated in a 
YAP injected recovery of a CCN2 deleted phenotype (Moon et al., 2020). Originally, the 
CCN2 deleted EC’s displayed decreased cell proliferation, junctional density, and 
vascular area in comparison to the normal CCN2 wildtype expressed EC’s in the retina. 
This was also compounded with a leaky and permeable vasculature. However, adenovirus 
mediated injection of YAP increased vascular area, junctional density, cell proliferation, 
and gene targets of YAP as well. Quantitative PCR of mRNA in the rescued phenotype 
displayed increased expression of genes associated with cell adhesion, cell migration, 
differentiation, and ECM remodeling (Figure 26). Such comprehensive investigation 






Figure 26. YAP injection into CCN2 deleted phenotype promotes rescue. (A) 
Vascular area percentage was drastically increased once the adenovirus YAP was 
introduced via injection into the CCN2 deleted phenotype. (B) Significant increase in 
junctional density was observed upon injection of YAP, yet not equivalent to wildtype 
CCN2 expressing levels. (C) Increased levels of proliferation from YAP mediated rescue 
of the CCN2 deleted phenotype. (D) YAP mediated injection lead to changes in the 
expression levels of YAP target genes. Taken from (Moon et al., 2020). 
 
CCN2 and MMP2 
While it is understood that CCN2 plays a critical role in driving pathological 
fibroproliferative diseases via angiogenic pathways, the mechanism for causing such 
changes in unknown. However, studies have shown that CCN2 promotes 
neovascularization through expression of matrix metalloproteinase (MMP)-2, a protein 
which drives vascular remodeling through modifications in ECM and non-ECM proteins. 
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MMP2 is also said to promote migration and invasion of EC’s as well as allow formation 
of new vascular patterns (Chintala et al., 2012).  
CCN2’s presence in pathological neovascularization was evident when mouse retinas 
exposed to OIR exhibited a remarkable increase in CCN2 mRNA. OIR induced mice 
retinas displayed a 6.4-fold increase in CCN2 mRNA expression levels, nearly 3.5 times 
higher than the normoxic controls (Figure 27). 
 
Figure 27. OIR induces upregulation in CCN2 mRNA expression levels. In 
comparison to normoxic controls between stages P12 and P17, OIR induced mouse 
retinas displayed nearly 3.5 times larger fold change in CCN2 mRNA expression levels. 
Taken from (Chintala et al., 2012). 
With OIR promoting an increase in CCN2 mRNA expression levels, further studies were 
conducted to generate a prognosis on the effects that overexpression of CCN2 had on 
vascular growth and formation post-OIR. This was accomplished through the injection of 
a lentivirus vector expressing GFP and the CCN2 promoter post-OIR. (Chintala et al., 
2012). While vaso-obliteration between the control and ectopically expressed CCN2 
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retinas remained the same, retinal neovascular tuft and cell nuclei formation were 
observed to increase in the overexpressed CCN2 retina (Figure 28).  
 
Figure 28. Overexpression of CCN2 post-OIR promotes retinal neovascularization. 
(A) OIR-induced Retina flat-mount preparations showing P12 (a & b) and P17 (c & d) 
vascular growth. Panels a and c represent vascular growth for control-plasmid injected 
retinas whereas b and d represent vascular growth for overexpressed CCN2 injected 
retinas. Panels e and f showcase computer generated instances of vaso-obliteration while 
panels g and h showcase computer generated instances of neovascular tufts in white and 
yellow respectively. (B) Vascular area over the total retinal surface allows for one to 
determine the extent of vaso-obliteration that OIR has on the respective retinas. (C) 
Neovascularization data between control and overexpressed CCN2 retinas post-OIR 
showed in increase in neovascularization for the CCN2 injected retinas. (D) Higher 
amounts of neovascular cells were present in the CCN2 injected post-OIR retinas. Taken 
from (Chintala et al., 2012). 
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Connections between CCN2 and MMP2 were observed when post-OIR retinal 
vasculature containing overexpressed CCN2 levels was studied in cohesion with genes 
known to be associated with neovascularization. Such genes include VEGF, Tumor 
Necrosis Factor-α (TNF-α), Interleukin-1β (IL-1 β), and MMP2 (Chintala et al., 2012). 
MMP2 was found to contain significantly increased mRNA levels as a result of the OIR, 
and even higher levels when combined with the vector-injection to overexpress CCN2. 
Further analysis through western blot staining showed increased levels of MMP2 in its 
active form of 68 kilodaltons over its latent form of 72 kilodaltons in the post-OIR CCN2 
injected retina (Figure 29). 
 
Figure 29. Overexpression of CCN2 in post-OIR mice promotes increased 
expression of MMP2. (A) MMP-2 mRNA levels significantly increased when 
comparing control retinal vasculature cells to overexpressed-CCN2 retinal vascular cells. 
(B) Increase in latent form MMP-2 in post-OIR retinal cells after injection and 
overexpression by CCN2. (C) Increase in active form MMP-2 in post-OIR retinal cells 
after injection and overexpression by CCN2. (D)  MMP2 present in higher levels in the 
CCN2 injected post-OIR retinal cells. (E) Active form of MMP2 (68 kilodalton band) 
observed in higher levels in the CCN2 injected plasmid post-OIR rather than control 
injected plasmid. Taken from (Chintala et al., 2012). 
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Studies on loss of CCN2 function only further solidified the relationship between the 
ECM signaling protein and MMP-2. Using vector plasmids to inhibit and perturb CCN2 
expression, the effects of deficient CCN2 on both MMP-2 expression and phenotype 
were observed. In comparison to controls, blood vessel development and growth across 
the retina was found to be delayed rather than inhibited (Chintala et al., 2012). However, 
OIR mice exhibited decreases in levels of neovascularization. In terms of vaso-
obliteration, neither OIR nor non-OIR affected mice displayed any change (Figure 30). 
Genotypically, VEGF and MMP-2 expression levels were found to decrease in the CCN2 




Figure 30. CCN2 knockout decreases neovascularization and MMP-2 levels. (A) The 
lack of CCN2 expression in retinas delays blood vessel development as well as decreases 
neovascularization. Panel a-c represent control, antisense DNA fragment, and C-terminal 
deleted CCN2 expressing genotypes, respectively. (B) The effects of CCN2 expression 
levels on neovascularization post-OIR. Panels a-c are the same as in (A). (C) Changes in 
CCN2 expression again displayed no significant changes in vaso-obliteration levels. (D) 
Neovascularization levels dropped off in both modified CCN2 injected vectors when 
compared to the wildtype control. (E) VEGF displayed decreased mRNA expression 
levels in both antisense DNA fragment and C-terminal deleted CCN2 expressing 
genotypes. (F-G) Decreases in MMP-2 mRNA, latent form, and active form expression 
levels were observed to decrease significantly in CCN2 deficient mice. Taken from 





CCN2’s connection with MMP-2’s expression was further analyzed through MMP-2’s 
promoter region. In an effort to understand which region of the promoter interacted 
CCN2 to upregulate MMP-2, EC’s were transfected with both CCN2 and modified 
MMP-2 promoter plasmids (Chintala et al., 2012). Loss of the p-53 cis-acting element in 
the MMP-2 region caused the greatest decrease in MMP-2 promoter responsiveness 
(Chintala et al., 2012). Known for being both an active tumor suppressor and 
transcription factor gene, p-53 has also been known to have targets downstream affiliated 
with cell growth, apoptosis, and even angiogenesis (Giovanni & Rathore, 2012). Such 
interactions were further proven when inhibition of CCN2 caused a decrease in retinal 
neovascularization via a loss in p-53 enrichment of the MMP-2 promoter region (Figure 
31). Further research showed an increase in p-53 enrichment of MMP-2 in OIR-induced 
retinas, suggesting that p53 plays a role in regulating the pathological angiogenic process 






Figure 31. Effects of OIR and CCN2 expression levels of p53 enrichment of MMP-2 
promoter. (A) Levels of p53 shown to be expressed in larger amounts post OIR as 
opposed to normoxic-like conditions. However, modified CCN2 injected plasmids 
inhibited the expression levels of p53 significantly. (B) p53 enrichment of MMP-2 was 
also shown to increase drastically following OIR, while decreasing substantially as a 
result of the modified CCN2 expressing plasmids transfected into the retina. (Both 
modified CCN2 plasmids were utilized to inhibit overall CCN2 expression as they were 













Understanding the mechanistic pathways associated with neovascularization and 
angiogenesis are critical for creation of drug therapies and treatments for diseases 
associated with the process. Pathologies such as cardiovascular risk factors in diabetes, 
dyslipidemia, hypertension, ischemia and more act as mechanical stimuli that can 
influence blood vessel vasculature (Chaqour, 2020). Such pre-existing health conditions 
have been known to occur in previously mentioned “blinding diseases” of the eye.   
Furthermore, evidence has long supported the role of angiogenesis in promoting tumor 
growth (Zuazo-Gaztelu & Casanovas 2018). Research with regards to angiogenesis on 
both of these major pathologies has showcased the impact that the ECM has had on the 
process of angiogenesis. As a result, research of ECM proteins, particularly signaling 
proteins CCN1 and CCN2 are critical in understanding the connected roles they play in 
modulating pathological angiogenic growth .  
More than 40 years have passed since the discovery of angiogenic inhibition being 
utilized to treat tumor growth (Sherwood et al., 1971). Since then, numerous FDA-
approved angiogenesis inhibitors such as sunitinib (Sutent) and bevacizumab (Avastin) 
have been utilized as a form of therapy for mitigation of tumor growth. (Motzer et al., 
2006; Salgaller, 2003). Furthermore, anti-VEGF therapy has been utilized on numerous 
occasions to treat angiogenesis in tumors due to its important role in the pathway 
(Siermerink et al., 2013). However, there is an argument to be made against the usage of 
anti-VEGF therapies. First, monthly anti-VEGF injections are both burdensome on 
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patients as well as healthcare as a whole. Secondly, VEGF and its receptors regulate 
physiological function in the retina. Anti-VEGF therapy, while beneficial in inhibiting 
tumor growth in cancer, would indirectly also cause interference in proper retinal 
function (Siermerink et al., 2013). Furthermore, evidence has been shown that 
angiogenesis can occur without the usage of VEGF (Benedito et al., 2012). This has 
prompted research to be conducted in discovering new determinants in the angiogenic 
process.  
The usage of CCN1 and CCN2 proteins as a means of developing therapies can be seen 
as a very promising first step in determining downstream regulators affiliated with 
angiogenic processes. After all, cell-cell and cell-matrix interactions are important for 
proper blood vessel growth, integrity, and modification. In addition, cell signaling 
proteins in the CCN family have been shown to regulate process of blood vessel growth 
via angiogenesis, neovascularization, and even in pathological processes such as fibrosis, 
ischemia, inflammation, and oncogenesis (Chintala et al., 2012; Leask, 2017; Perbal, 
2006; Perrot et al., 2015; Todorovicc et al., 2005; Tong et al., 2009). As a result, 
knockout and overexpression studies conducted with these proteins can help provide 
evidence and connections with other proteins known to be affiliated with pathological 
angiogenic processes.  
Studies previously mentioned have shown promising results establishing a connection 
between CCN1 and CCN2 to angiogenic neovascularization and vasculature integrity 
(Moon et al., 2020; Lee et al., 2019). In addition, proteins known to be affiliated with 
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angiogenic processes such as YAP, MMP-2, and p53 have been proven to display either 
direct or indirect interactions with either CCN1 and CCN2, further bolstering the role that 
the two signaling proteins display in blood vessel growth. It has also been shown that 
activation of the Rho-GTPase pathway due to mechanical tension cause expression of 
CCN1 and CCN2, which also (Chowdhury & Chaqour 2004; Han et al. 2003). Most 
importantly, the Rho-GTPase pathway is known for causing increased matrix deposition 
and causing fiber realignment. These pathogenic factors have been connected to a 
multitude of cardiovascular and eye diseases as well as aging, cancer and diabetes (Kim 
et al. 2019; Lacolley et al. 2009; Zhang et al. 2019).  
Although evidence supports the interaction of both CCN1 and CCN2 in causing 
pathological angiogenic processes through cell signaling, it would be naïve to assume 
that they are the primarily drivers of pathological angiogenic growth. The reality is that 
they are merely the keys in the ignition to start the pathway for a multitude of pathways 
in the body. By understanding the standing outreach that these two signaling proteins 
have in the ECM, further research can be conducted on more specific molecules that 
directly cause angiogenic growth. The goal for research regarding CCN1 and CCN2 is 
not to create anti-CCN1 or CCN2 drug therapies, but rather further attempt to understand 
the role that other genes have on the expression levels of the cells signaling proteins. 
Through this process of constant testing and elimination, the true sources for angiogenic 
growth under certain ECM changes can be uncovered, making way for therapeutic 
advancements and furthering our understanding on the subject.  
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Conclusions and Future Directions 
Understanding role of CCN1 and CCN2 in driving downstream angiogenic factors 
through cell signaling pathways will allow for future gene targeted therapies to be created 
in order to treat pathological angiogenesis-linked diseases such as DR, AMD and ROP as 
well as various forms of cancers. Now that an establishment has been made between the 
ECM and angiogenic processes, downstream targeted pathways can be further analyzed. 
Such analysis will provide further insight into the direct effectors of pathological 
neovascularization and angiogenesis. From this, specific therapies and treatments can be 
crated that are able to mitigate unnecessary vascular growth in the multitude of eye 
diseases as well as inhibit tumor size and expansion without perturbing normal 
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